<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02421367</url>
  </required_header>
  <id_info>
    <org_study_id>S-14-13</org_study_id>
    <secondary_id>WRAIR # 2195</secondary_id>
    <secondary_id>201658</secondary_id>
    <nct_id>NCT02421367</nct_id>
  </id_info>
  <brief_title>Study of Varying Injection Schedules of TDENV-PIV Vaccine With AS03B Adjuvant and Placebo in Healthy US Adults</brief_title>
  <official_title>A Phase 1/2, Randomized, Observer-blind Study of Varying Injection Schedules of a Tetravalent Dengue Virus Purified Inactivated Vaccine (TDENV-PIV) With AS03B Adjuvant and Placebo in Healthy Adults in the US</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>U.S. Army Medical Research and Development Command</agency>
      <agency_class>U.S. Fed</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Walter Reed Army Institute of Research (WRAIR)</agency>
      <agency_class>U.S. Fed</agency_class>
    </collaborator>
    <collaborator>
      <agency>GlaxoSmithKline</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>U.S. Army Medical Research and Development Command</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is being conducted to evaluate the safety and immunogenicity and antibody&#xD;
      persistence of the candidate dengue vaccine.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">August 2015</start_date>
  <completion_date type="Actual">March 2018</completion_date>
  <primary_completion_date type="Actual">December 2016</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Single (Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of solicited local adverse events related to product</measure>
    <time_frame>7-day follow-up period after each dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Intensity of solicited local adverse events related to product</measure>
    <time_frame>7-day follow-up period after each dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of unsolicited adverse events related to product</measure>
    <time_frame>28-day follow-up period after each dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Intensity of unsolicited adverse events related to product</measure>
    <time_frame>28-day follow-up period after each dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Grade 2 laboratory abnormalities</measure>
    <time_frame>7-day follow-up period after each dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Grade 3 laboratory abnormalities</measure>
    <time_frame>7-day follow-up period after each dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of serious adverse events from day 0 through 28 days after the last dose</measure>
    <time_frame>7 months after first dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of potential immune-mediated diseases from Day 0 through 28 days after the last dose</measure>
    <time_frame>7 months after first dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Neutralizing antibody titers to each DENV type</measure>
    <time_frame>Day 0 and 28 days after the second and third doses of TDENV-PIV</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of general adverse events related to product</measure>
    <time_frame>7-day follow-up period after each dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Intensity of solicited general adverse events related to product</measure>
    <time_frame>7-day follow-up period after each dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of medically attended AEs related to product</measure>
    <time_frame>Day 0 through 28 days after the last dose</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of potential immune-mediated diseases from post Month 7 to Study End</measure>
    <time_frame>7 months after first dose to the end of study</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of serious adverse events related to product</measure>
    <time_frame>7 months after first dose to the end of study</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Neutralizing antibody titers to each DENV type</measure>
    <time_frame>56 days after the second dose of active vaccine</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Seropositivity status for each DENV type</measure>
    <time_frame>28 days after the second dose of active vaccine for all groups</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of medically attended AEs from post Month 7 to Study End</measure>
    <time_frame>7 months after first dose to the end of study</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Neutralizing antibody titers to each DENV type for the TDENV-PIV (0-1-6) group</measure>
    <time_frame>56 days after the third dose of active vaccine</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Neutralizing antibody titers to each DENV type</measure>
    <time_frame>4 months after the last dose of active vaccine</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Neutralizing antibody titers to each DENV type</measure>
    <time_frame>6 months after the last dose of active vaccine</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Neutralizing antibody titers to each DENV type</measure>
    <time_frame>9 months after the last dose of active vaccine</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Neutralizing antibody titers to each DENV type</measure>
    <time_frame>12 months after the last dose of active vaccine</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Seropositivity status for each DENV type for the TDENV-PIV (0-1-6) group</measure>
    <time_frame>28 days after the third dose of active vaccine</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Seropositivity status for each DENV type for the TDENV-PIV (0-1-6) group</measure>
    <time_frame>56 days after the third dose of active vaccine</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Seropositivity status for each DENV type</measure>
    <time_frame>4 months after the last dose of active vaccine for all groups</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Seropositivity status for each DENV type</measure>
    <time_frame>6 months after the last dose of active vaccine for all groups</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Seropositivity status for each DENV type</measure>
    <time_frame>9 months after the last dose of active vaccine for all groups</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Seropositivity status for each DENV type</measure>
    <time_frame>12 months after the last dose of active vaccine for all groups</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">140</enrollment>
  <condition>Dengue</condition>
  <arm_group>
    <arm_group_label>TDENV-PIV (0-1)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The intervention is a tetravalent dengue virus purified inactivated vaccine (1µg/DENV type) with adjuvant, AS03B.&#xD;
The placebo is sodium chloride.&#xD;
TDENV-PIV vaccine and placebo will be administered in a single 0.5 mL dose intramuscularly in the non-dominant (whenever possible) deltoid region of the upper arm.&#xD;
The intervention will be administered on Day 0 and Day 28. The placebo will be administered on Day 84 and Day 168.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>TDENV-PIV (0-1-6)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The intervention is a tetravalent dengue virus purified inactivated vaccine (1µg/DENV type) with adjuvant, AS03B.&#xD;
The placebo is sodium chloride.&#xD;
TDENV-PIV vaccine and placebo will be administered in a single 0.5 mL dose intramuscularly in the non-dominant (whenever possible) deltoid region of the upper arm.&#xD;
The intervention will be administered on Day 0, Day 28, and Day 168. The placebo will be administered on Day 84.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>TDENV-PIV (0-3)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The intervention is a tetravalent dengue virus purified inactivated vaccine (1µg/DENV type) with adjuvant, AS03B.&#xD;
The placebo is sodium chloride.&#xD;
TDENV-PIV vaccine and placebo will be administered in a single 0.5 mL dose intramuscularly in the non-dominant (whenever possible) deltoid region of the upper arm.&#xD;
The intervention will be administered on Day 84 and Day 168. The placebo will be administered on Day 0 and Day 28.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>TDENV-PIV with AS03B adjuvant. Placebo: 0.9% Sodium Chloride Solution.</intervention_name>
    <description>Tetravalent dengue virus purified inactivated vaccine (1 µg/virus type)</description>
    <arm_group_label>TDENV-PIV (0-1)</arm_group_label>
    <arm_group_label>TDENV-PIV (0-1-6)</arm_group_label>
    <arm_group_label>TDENV-PIV (0-3)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Subjects must be able to provide written informed consent.&#xD;
&#xD;
          2. Subjects must be healthy as established by medical history and clinical examination at&#xD;
             study entry&#xD;
&#xD;
          3. Subjects who the investigator believes can and will comply with the requirements of&#xD;
             the protocol (e.g., completion of the diary cards, return for follow-up visits, etc.)&#xD;
&#xD;
          4. Subjects at WRAIR CTC must be able to pass Department of Defense (DoD) base entry&#xD;
             requirements, including the possession of a valid government issued ID card.&#xD;
&#xD;
          5. Male or non-pregnant, non-breastfeeding female between 20 and 49 years of age&#xD;
             (inclusive) at the time of consent&#xD;
&#xD;
          6. Female subjects of non-childbearing potential (non-childbearing potential is defined&#xD;
             as having had one of the following: a tubal ligation at least 3 months prior to&#xD;
             enrollment, a hysterectomy, an ovariectomy, or is post-menopausal).&#xD;
&#xD;
          7. Female subjects of childbearing potential may be enrolled in the study, if all of the&#xD;
             following apply:&#xD;
&#xD;
               -  Practiced adequate contraception (see Definition of Terms, section 5) for 30 days&#xD;
                  prior to vaccination&#xD;
&#xD;
               -  Has a negative urine pregnancy test on the day of vaccination&#xD;
&#xD;
               -  Agrees to continue adequate contraception until two months after completion of&#xD;
                  the vaccination series.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Use of any investigational or non-registered product (drug or vaccine) other than the&#xD;
             study vaccines/placebo during the period starting 30 days preceding the first dose of&#xD;
             study vaccine/placebo and/or planned use during the study period&#xD;
&#xD;
          2. Chronic administration (defined as more than 14 days in total) of immunosuppressants&#xD;
             or other immune-modifying drugs during the period starting 90 days prior to the first&#xD;
             vaccine/placebo dose (for corticosteroids, this will mean prednisone &gt;=5mg/day or&#xD;
             equivalent; inhaled, intranasal and topical steroids are allowed)&#xD;
&#xD;
          3. Planned administration or administration of a vaccine/product not planned in the study&#xD;
             protocol during the period starting 30 days prior to the first dose of vaccine/placebo&#xD;
             until 30 days after the last dose of study vaccine/placebo (routine influenza&#xD;
             vaccination will be allowed as long as it is not administered within 14 days of the&#xD;
             vaccine/placebo, and will not lead to study exclusion although it should be reported&#xD;
             to the PI)&#xD;
&#xD;
          4. History of dengue infection or dengue illness, or history of flavivirus vaccination&#xD;
             (e.g., yellow fever, tick-borne-encephalitis virus [TBEV], Japanese encephalitis, and&#xD;
             dengue)&#xD;
&#xD;
          5. Planned administration of any flavivirus vaccine for the entire study duration&#xD;
&#xD;
          6. Concurrently participating in another clinical study, at any time during the study&#xD;
             period, in which the subject has been or will be exposed to an investigational or a&#xD;
             non-investigational product (pharmaceutical product or device)&#xD;
&#xD;
          7. Any confirmed or suspected immunosuppressive or immunodeficient condition, based on&#xD;
             medical history and physical examination (no laboratory testing required)&#xD;
&#xD;
          8. Family history of congenital or hereditary immunodeficiency&#xD;
&#xD;
          9. Autoimmune disease or history of autoimmune disease&#xD;
&#xD;
         10. History of any reaction or hypersensitivity likely to be exacerbated by any component&#xD;
             of the study vaccine/placebo or related to a study procedure&#xD;
&#xD;
         11. Major congenital defects or serious chronic illness&#xD;
&#xD;
         12. History of any neurological disorders or seizures&#xD;
&#xD;
         13. Diagnosed with excessive daytime sleepiness (unintended sleep episodes during the day&#xD;
             present almost daily for at least 1 month) or narcolepsy; or history of narcolepsy in&#xD;
             a subject's parent, sibling, or child&#xD;
&#xD;
         14. Acute disease and/or fever (≥37.5°C/99.5°F oral body temperature) at the time of&#xD;
             enrollment: note that a subject with a minor illness such as mild diarrhea, mild upper&#xD;
             respiratory infection, etc., without fever, may be enrolled at the discretion of the&#xD;
             investigator&#xD;
&#xD;
         15. Acute or chronic, clinically significant pulmonary, cardiovascular, hepatic or renal&#xD;
             functional abnormality, as determined by physical examination or laboratory screening&#xD;
             tests&#xD;
&#xD;
         16. Administration of immunoglobulins and/or any blood products during the period starting&#xD;
             90 days preceding the first dose of study vaccine/placebo or planned administration&#xD;
             during the study period&#xD;
&#xD;
         17. Recent history of chronic alcohol consumption (more than 2 drinks per day and/or drug&#xD;
             abuse (based on subject reported history)&#xD;
&#xD;
         18. Pregnant or breastfeeding female or female currently planning to become pregnant or&#xD;
             planning to discontinue adequate contraception&#xD;
&#xD;
         19. A planned move to a location that will prohibit participating in the trial until Study&#xD;
             End for the participant&#xD;
&#xD;
         20. Any other condition which, in the opinion of the investigator, prevents the subject&#xD;
             from participating in the study.&#xD;
&#xD;
         21. Subject seropositive for hepatitis B surface antigen (HBsAg), hepatitis C virus&#xD;
             antibodies (anti-HCV), or human immunodeficiency virus antibodies (anti-HIV)&#xD;
&#xD;
         22. Safety laboratory test results at screening that are deemed clinically significant or&#xD;
             more than Grade 1 deviation from normal&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>49 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Leyi Lin, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>USAMRMC/WRAIR</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Maryland, Center for Vaccine Development,</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>WRAIR, Clinical Trials Center</name>
      <address>
        <city>Silver Spring</city>
        <state>Maryland</state>
        <zip>20910-7500</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2019</verification_date>
  <study_first_submitted>April 15, 2015</study_first_submitted>
  <study_first_submitted_qc>April 15, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 20, 2015</study_first_posted>
  <last_update_submitted>September 24, 2019</last_update_submitted>
  <last_update_submitted_qc>September 24, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">September 25, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dengue</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

